CAPTRUST Financial Advisors’s Fate Therapeutics FATE Stock Holding History
Bought
Maintained
Sold
Other funds holding FATE
CAPTRUST Financial Advisors's FATE Position: Q3 2026 in Review
CAPTRUST Financial Advisors reduced its Fate Therapeutics (FATE) stake by 68% in Q3 2026, selling an estimated $130K and leaving 23,317 shares worth $55.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3239.
CAPTRUST Financial Advisors first reported a position in FATE in Q1 2021 and has held it in 13 quarters since. The position peaked at $199K in Q2 2026. 142 funds tracked by Wall St. Rank hold FATE as of Q3 2026.
- CAPTRUST Financial Advisors held 23,317 shares of Fate Therapeutics worth $55.3K as of Q3 2026.
- CAPTRUST Financial Advisors sold 50,295 Fate Therapeutics shares in Q3 2026, an estimated $130K.
- Fate Therapeutics made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q3 2026, its #3239 holding.
- CAPTRUST Financial Advisors first reported a position in Fate Therapeutics in Q1 2021 and has held it in 13 quarters since.
- CAPTRUST Financial Advisors's Fate Therapeutics position peaked at $199K in Q2 2026.
- 142 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2026.
Based on CAPTRUST Financial Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.